|
Gender
| |
|
Female
|
82 (47)
|
|
Male
|
91 (53)
|
|
Affected side
| |
|
Left
|
91 (53)
|
|
Right
|
82 (47)
|
|
First SSNHL
|
124 (72)
|
|
Recurrent SSNHL
|
49 (28)
|
|
Audiogram pattern
| |
|
Low-frequency
|
9 (5)
|
|
Mid-frequency
|
12 (7)
|
|
High-frequency
|
63 (36)
|
|
Flat
|
55 (32)
|
|
Total deafness
|
34 (20)
|
|
Contralateral ear
| |
|
Normal hearing
|
97 (56)
|
|
Abnormal hearing
|
40 (44)
|
|
Tinnitus, additionally
| |
|
Yes
|
139 (80)
|
|
No
|
34 (20)
|
|
Vertigo
| |
|
Yes
|
33 (19)
|
|
No
|
140 (81)
|
|
Smoking
| |
|
Yes
|
24 (14)
|
|
No
|
149 (86)
|
|
Charlson Comorbidity Index
| |
|
Index = 0
|
121 (70)
|
|
Index = 1
|
27 (16)
|
|
Index = 2
|
19 (11)
|
|
Index ≥ 3
|
6 (4)
|
|
Vascular risk profile
| |
|
Yes
|
93 (54)
|
|
No
|
80 (46)
|
|
Metabolic syndrome
| |
|
Yes
|
4 (2)
|
|
No
|
169 (98)
|
|
Final absolute hearing gain (∆6PTA)
| |
|
0 dB
|
24 (14)
|
|
1-19 dB
|
110 (64)
|
|
≥20 dB
|
39 (23)
|
| |
Median, range
|
|
Age (years)
|
64, 18-88
|
|
Interval onset to therapy (days)
|
3.5, 0-28
|
|
Hearing loss, initial (6PTA; dB)
|
42.5, 14.2-110
|
|
Hearing loss, final (6 PTA; dB)
|
30, 0.8-105.8
|
|
Hearing gain, absolute (∆6PTA; dB)
|
9, 0-100
|
|
Hearing loss, contralateral ear, initial (6PTA)
|
17.5, 0-120
|
